Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03841110 · ClinicalTrials.gov registry record · Phase 1
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by Fate Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT03841110 is a Phase 1 study that has completed, run by Fate Therapeutics. The registered enrollment target is 37 participants.
The verdict
NCT03841110, a Phase 1 study, has completed, sponsored by Fate Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance. The preclinical data provide compelling evidence supporting the clinical investigation of FT500 as monotherapy and in combination with ICI in participants with advanced solid tumors.
Interventions
- DRUG Pembrolizumab
- DRUG Cyclophosphamide
- DRUG Atezolizumab
- DRUG Nivolumab
- DRUG FT500
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2019-02-15 |
| Est. Completion | 2022-11-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03841110
The ClinicalTrials.gov registry entry for NCT03841110 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fate Therapeutics, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT03841110 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03841110 about?
NCT03841110 is a clinical study titled "FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors". FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance. The preclinical data provide compelling evidence supporting the clinical investigation of FT500...
What is the current status of trial NCT03841110?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2019-02-15. Estimated completion is 2022-11-15.
What interventions are being tested in trial NCT03841110?
The interventions under investigation include: Pembrolizumab (DRUG), Cyclophosphamide (DRUG), Atezolizumab (DRUG), Nivolumab (DRUG), FT500 (DRUG).
Who is sponsoring clinical trial NCT03841110?
This trial is sponsored by Fate Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.